Text Size
366 studies found for:    nasopharyngeal cancer | "Nasopharyngeal Carcinoma"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma;   Adverse Effect of Radiation Therapy;   Brain Necrosis
Interventions: Drug: bevacizumab;   Drug: Methylprednisolone
22 Active, not recruiting Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Drug: Gemcitabine and cisplatin;   Drug: Cisplatin
23 Unknown † Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: 5-fluorouracil (5-FU)
24 Completed Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)
Condition: Nasopharyngeal Carcinoma
Intervention:
25 Recruiting Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Capecitabine;   Drug: Adjuvant chemotherapy using PF (5-Fluorouracil );   Drug: Induction chemotherapy using PF (5-Fluorouracil)
26 Completed Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
Condition: Nasopharyngeal Carcinoma
Intervention:
27 Completed
Has Results 		Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: C225 (cetuximab)
28 Recruiting Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: FOSCAN
29 Recruiting Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma
Conditions: Chemoradiation;   Nasopharyngeal Carcinoma
Interventions: Drug: PF (cisplatin and 5-fluorouracil) group;   Drug: TPF (docetaxel plus cisplatin and 5-fluorouracil) group
30 Completed Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount
Condition: Nasopharyngeal Carcinoma
Intervention:
31 Active, not recruiting Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Radiation: Proton/Photon Radiotherapy;   Drug: Cisplatin;   Drug: Fluorouracil
32 Terminated A Phase III Study of Radiotherapy With or Without Adjuvant C/T in Advanced Stage Nasopharyngeal Carcinoma Patients
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Cisplatin,5-FU,Leucovorin
33 Completed EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
Conditions: Nasopharyngeal Cancer;   EBV Infections
Interventions: Biological: EBV specific CTL Infusion;   Biological: Anti CD45 monoclonal antibody
34 Recruiting Screening for Nasopharyngeal Carcinoma in High Risk Populations
Conditions: Nasopharyngeal Cancer;   Screening
Intervention:
35 Recruiting Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Nedaplatin;   Drug: Cisplatin
36 Recruiting A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
37 Recruiting A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Cancer;   Epstein Barr Virus Infections
Intervention: Drug: MVA-EBNA1/LMP2 vaccine
38 Recruiting Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Cetuximab
39 Active, not recruiting Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Biological: Epstein-Barr virus-specific adoptive T-cells immunotherapy
40 Recruiting A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Condition: Nasopharyngeal Cancer
Intervention: Drug: Adjuvant chemotherapy (gemcitabine and cisplatin)
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years